Close
B- and T-cells in Autoimmunity
Mike Ehrenstein is a Consultant Rheumatologist at UCL Hospitals, where he leads the New Therapies Clinic for Inflammatory Arthritis, and is Professor of Experimental Rheumatology at UCL. His key interests are in new therapies for rheumatoid arthritis and other autoimmune rheumatic diseases, using novel biologic therapies as a tool to understand and manipulate the aberrant immune responses found in patients with autoimmunity. This includes developing a biomarker to predict response to anti-TNF therapy, which will enable this treatment to be given to only those patients that will respond, and devising a clinical trial to test the importance of the B cell cytokine BAFF in SLE patients who have been treated with rituximab. The long-term goal is to define the cellular and molecular mechanisms that switch off inflammation.
After studying medicine at The Middlesex Hospital, he trained in Rheumatology at The Hammersmith Hospital and Addenbrooke's Hospital, Cambridge. He was awarded a PhD at UCL and is currently a member of The Biomedical Sciences Panel of the Arthritis Research Campaign and a member of The Expert Advisory Group to the Commission for Human Medicines (MHRA) on Immunology and Rheumatology.
Visit Mike Ehrenstein's IRIS Profile >
Email address: m.ehrenstein@ucl.ac.uk